Table 2. Change in kidney function and the risk of death.

Model 1 adjusted for age, race, gender, diabetes mellitus, hypertension, cardiovascular disease, hyperlipidemia, peripheral artery disease, cerebrovascular disease, chronic lung disease, hepatitis C, HIV, dementia and eGFR at time of cohort entry (T0). Reference group is patients with stable kidney function (eGFR slope).

	1-year HR (CI)	3-year HR (CI)	5-year HR (CI)	9-year HR (CI)
Model 1
Improved eGFR slope	2.04 (1.94–2.15)	1.59 (1.55–1.64)	1.43 (1.40–1.46)	1.33 (1.31–1.35)
Declining eGFR slope	2.16 (2.05–2.26)	1.58 (1.53–1.63)	1.46 (1.42–1.50)	1.35 (1.32–1.37)
Model 1 + annual percentage weight change
Improved eGFR slope	1.76 (1.63–1.89)	1.45 (1.39–1.50)	1.38 (1.34–1.42)	1.30 (1.27–1.32)
Declining eGFR slope	1.57 (1.47–1.68)	1.39 (1.34–1.43)	1.30 (1.27–1.34)	1.26 (1.24–1.28)
Model 1 + annual percentage weight change + albuminuria
Improved eGFR slope	1.72 (1.38–2.14)	1.39 (1.26–1.54)	1.29 (1.21–1.38)	1.22 (1.17–1.27)
Declining eGFR slope	1.44 (1.19–1.75)	1.33 (1.22–1.45)	1.20 (1.13–1.27)	1.21 (1.17–1.25)